UY40173A - Composiciones que comprenden aticaprant - Google Patents
Composiciones que comprenden aticaprantInfo
- Publication number
- UY40173A UY40173A UY0001040173A UY40173A UY40173A UY 40173 A UY40173 A UY 40173A UY 0001040173 A UY0001040173 A UY 0001040173A UY 40173 A UY40173 A UY 40173A UY 40173 A UY40173 A UY 40173A
- Authority
- UY
- Uruguay
- Prior art keywords
- compositions
- aticaprant
- methods
- description relates
- tablet form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317471P | 2022-03-07 | 2022-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY40173A true UY40173A (es) | 2023-09-29 |
Family
ID=85980700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001040173A UY40173A (es) | 2022-03-07 | 2023-03-06 | Composiciones que comprenden aticaprant |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20230277500A1 (https=) |
| EP (1) | EP4489730B1 (https=) |
| JP (1) | JP2025508069A (https=) |
| KR (1) | KR20240152410A (https=) |
| CN (1) | CN119156202A (https=) |
| AU (1) | AU2023231767A1 (https=) |
| CA (1) | CA3254546A1 (https=) |
| CL (1) | CL2024002648A1 (https=) |
| CO (1) | CO2024012454A2 (https=) |
| IL (1) | IL315415A (https=) |
| JO (1) | JOP20240196A1 (https=) |
| MX (1) | MX2024010977A (https=) |
| TW (1) | TW202400135A (https=) |
| UY (1) | UY40173A (https=) |
| WO (1) | WO2023170554A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| TR200103237T2 (tr) | 1999-05-12 | 2002-04-22 | F. Hoffmann-La Roche Ag | İmidazodiazepin türevi |
| US20020052365A1 (en) | 2000-10-05 | 2002-05-02 | Mohler Hanns | Selective anxiolytic therapeutic agents |
| JP2004518654A (ja) | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| DE60319812T2 (de) | 2002-03-28 | 2009-04-23 | Wisys Technology Foundation, Inc., Madison | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| KR101025633B1 (ko) | 2002-09-19 | 2011-03-30 | 일라이 릴리 앤드 캄파니 | 오피오이드 수용체 안타고니스트로서의 디아릴 에테르 |
| ATE406360T1 (de) | 2003-03-07 | 2008-09-15 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| EP1613597B1 (en) | 2003-03-07 | 2007-11-07 | Eli Lilly and Company | 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| CA2549009A1 (en) | 2003-12-12 | 2005-07-07 | Eli Lilly And Company | Opioid receptor antagonists |
| ES2390459T3 (es) | 2003-12-22 | 2012-11-13 | Eli Lilly And Company | Antagonistas de receptores de opioides |
| DE602005022572D1 (de) | 2004-03-12 | 2010-09-09 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| ATE399164T1 (de) | 2004-03-12 | 2008-07-15 | Lilly Co Eli | Antagonisten des opioidrezeptors |
| EP1729759A4 (en) | 2004-03-12 | 2008-04-02 | Mclean Hospital Corp | SALVINORINE DERIVATIVES AND ITS USES |
| DE602005012380D1 (de) | 2004-03-15 | 2009-03-05 | Lilly Co Eli | 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit |
| EP1735268B1 (en) | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| JP5128578B2 (ja) | 2006-04-04 | 2013-01-23 | エモディス ゲーエムベーハー | 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 |
| EP2049481A2 (en) | 2006-08-09 | 2009-04-22 | SmithKline Beecham Corporation | Novel compounds as antagonists or inverse agonists for opioid receptors |
| EP2054383A2 (en) | 2006-08-09 | 2009-05-06 | SmithKline Beecham Corporation | Novel compounds as antagonists or inverse agonists at opioid receptors |
| KR20090051778A (ko) | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
| JP5345637B2 (ja) | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| AU2010316683B2 (en) * | 2009-11-09 | 2015-10-08 | Wyeth Llc | Tablet formulations of neratinib maleate |
| WO2012016569A1 (en) | 2010-08-05 | 2012-02-09 | Conrig Pharma Aps | Deuterated tandospirone derivatives as 5-ht1a receptor agonists |
| ES2631607T3 (es) | 2011-12-09 | 2017-09-01 | Research Triangle Institute, International | 4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa |
| ES2694352T3 (es) | 2013-12-20 | 2018-12-20 | H. Lundbeck A/S | Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas |
| WO2016156396A1 (en) | 2015-03-30 | 2016-10-06 | University Of Innsbruck | Diphenethylamine derivatives which are inter alia useful as analgesics and methods for their production |
| US10709685B2 (en) | 2015-05-28 | 2020-07-14 | Georgetown University | Use of methadone metabolites for treatment of anxiety and depression |
| CA2987912C (en) * | 2015-06-30 | 2023-01-24 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
| EP3468540A4 (en) | 2016-06-13 | 2020-03-18 | Board Of Regents Of the University Of Texas System | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN |
| US20190240293A1 (en) | 2016-07-26 | 2019-08-08 | Flagship Pioneering Innovations V, Inc. | Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response |
| US11292783B2 (en) | 2016-09-16 | 2022-04-05 | Research Triangle Institute | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| AU2018234931B2 (en) | 2017-03-17 | 2022-05-26 | Blackthorn Therapeutics, Inc. | Kappa opioid receptor antagonists and products and methods related thereto |
| PH12018000077B1 (en) * | 2017-07-05 | 2021-07-09 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US20190255036A1 (en) | 2018-02-16 | 2019-08-22 | Alexander Kariman | Compound and method for reducing neuropathic pain and depression |
| JP7416751B2 (ja) | 2018-03-23 | 2024-01-17 | ユニバーシティ オブ カンザス | 環状テトラペプチド類似体 |
| US11491144B2 (en) | 2018-03-30 | 2022-11-08 | The Florida State University Research Foundation, Incorporated | Methods of treating fragile X mental retardation syndrome |
| EP3870030A4 (en) | 2018-10-23 | 2022-08-03 | Blackthorn Therapeutics, Inc. | SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS |
| US20200171025A1 (en) * | 2018-11-29 | 2020-06-04 | Srinivasa Rao Parella | Pharmaceutical composition comprising brexpiprazole and process for preparation thereof |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| PH12023552963A1 (en) * | 2021-05-04 | 2024-03-11 | Janssen Pharmaceuticals Inc | Compositions and methods for the treatment of depression |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| AU2023231493A1 (en) | 2022-03-07 | 2024-10-24 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
-
2023
- 2023-03-06 WO PCT/IB2023/052097 patent/WO2023170554A1/en not_active Ceased
- 2023-03-06 EP EP23716356.3A patent/EP4489730B1/en active Active
- 2023-03-06 IL IL315415A patent/IL315415A/en unknown
- 2023-03-06 US US18/179,093 patent/US20230277500A1/en not_active Abandoned
- 2023-03-06 CA CA3254546A patent/CA3254546A1/en active Pending
- 2023-03-06 AU AU2023231767A patent/AU2023231767A1/en active Pending
- 2023-03-06 CN CN202380038806.7A patent/CN119156202A/zh active Pending
- 2023-03-06 KR KR1020247033299A patent/KR20240152410A/ko active Pending
- 2023-03-06 JP JP2024553421A patent/JP2025508069A/ja active Pending
- 2023-03-06 TW TW112108149A patent/TW202400135A/zh unknown
- 2023-03-06 UY UY0001040173A patent/UY40173A/es unknown
-
2024
- 2024-03-27 US US18/618,520 patent/US12201610B2/en active Active
- 2024-09-04 CL CL2024002648A patent/CL2024002648A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0196A patent/JOP20240196A1/ar unknown
- 2024-09-06 MX MX2024010977A patent/MX2024010977A/es unknown
- 2024-09-13 CO CONC2024/0012454A patent/CO2024012454A2/es unknown
-
2025
- 2025-01-16 US US19/023,669 patent/US20250228819A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3254546A1 (en) | 2023-09-14 |
| IL315415A (en) | 2024-11-01 |
| EP4489730B1 (en) | 2026-01-21 |
| JP2025508069A (ja) | 2025-03-21 |
| MX2024010977A (es) | 2024-12-06 |
| WO2023170554A1 (en) | 2023-09-14 |
| US20230277500A1 (en) | 2023-09-07 |
| EP4489730C0 (en) | 2026-01-21 |
| AU2023231767A1 (en) | 2024-10-24 |
| EP4489730A1 (en) | 2025-01-15 |
| US12201610B2 (en) | 2025-01-21 |
| CO2024012454A2 (es) | 2024-09-30 |
| US20240269110A1 (en) | 2024-08-15 |
| KR20240152410A (ko) | 2024-10-21 |
| TW202400135A (zh) | 2024-01-01 |
| CL2024002648A1 (es) | 2025-01-24 |
| US20250228819A1 (en) | 2025-07-17 |
| CN119156202A (zh) | 2024-12-17 |
| JOP20240196A1 (ar) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40173A (es) | Composiciones que comprenden aticaprant | |
| CO2019009258A2 (es) | Administración rápida y controlada de composiciones con efectos séquito restaurados | |
| CL2020002841A1 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| AR106768A1 (es) | Composiciones que comprenden cepas bacterianas | |
| MX366925B (es) | Inhibidores de ibat para el tratamiento de enfermedades hepaticas. | |
| BRPI0916188A2 (pt) | Série de composto para clareamento da pele (iluminação) | |
| MX2020003605A (es) | Manipulación del metabolismo de triptamina. | |
| AR112587A1 (es) | Psicosa-6-fosfato fosfatasa, composición para producir d-psicosa que comprende la enzima y métodos para producir d-psicosa utilizando la enzima | |
| PT3852525T (pt) | Método para obter uma população enriquecida de células estaminais mesenquimais funcionais, células obtidas a partir do mesmo e composições compreendendo as mesmas | |
| AR050717A1 (es) | Composiciones farmaceuticas | |
| BR112015012453A2 (pt) | método e composição para sincronizar o tempo de inseminação em leitoas | |
| MX381237B (es) | Composiciones edulcorantes que contienen rebaudiósidos d. | |
| CO2022005952A2 (es) | Extracto de algas concentrado | |
| CR11078A (es) | Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas | |
| CO6300935A2 (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
| MX2018007871A (es) | Composiciones para el cuidado personal. | |
| MX2020011923A (es) | Metodos y composiciones para incrementar los cuerpos cetonicos en animales. | |
| CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato | |
| MX2019008460A (es) | Metodos para tratar esclerosis multiple usando celulas t autologas. | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| CL2019003801A1 (es) | Nuevas formulaciones orales de belinostato. | |
| AR110808A1 (es) | Estilbenos naturales como edulcorantes o mejoradores del dulzor | |
| AR076520A1 (es) | Parasiticidas sanguineos. composicion | |
| BR112018000252A2 (pt) | métodos e composições farmacêuticas para intensificar atividades de eliminação de célula nk | |
| MX2022007720A (es) | Extractos enriquecidos con compuestos polifenolicos y metodos relacionados. |